Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.60 |
| ▸ | HPGD | P15428 | 3/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.60 |
| ▸ | NPC1 | O15118 | 3/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.56 |
| ▸ | MMP13 | P45452 | 8/20 | 0.55 |
| ▸ | MMP2 | P08253 | 6/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | GLA | P06280 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | ATM | Q13315 | 1/20 | 0.52 |
| ▸ | MMP14 | P50281 | 4/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23732403 | 1.00 | RAB9A (0.60) | RAB9AKDM4EALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL21355515 | 0.92 | RAB9A (0.67) | RAB9AKDM4EALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL15642755 | 0.87 | RAB9A (0.61) | RAB9AKDM4EALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL29475141 | 0.85 | RAB9A (0.53) | RAB9AKDM4EALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL21175334 | 0.85 | RAB9A (0.53) | RAB9AKDM4EALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL29475124 | 0.85 | RAB9A (0.53) | RAB9AKDM4EALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL21175271 | 0.85 | RAB9A (0.53) | RAB9AKDM4EALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL25025323 | 0.85 | RAB9A (0.53) | RAB9AKDM4EALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL31619692 | 0.85 | RAB9A (0.61) | RAB9AKDM4EALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL15642719 | 0.82 | RAB9A (0.55) | RAB9AKDM4EALDH1A1HPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12617783-B2 | Heterocyclic GLP-1R agonists | BIOMEA FUSION, INC. (US) | 2026-05-05 | — | — | US | disclosed |
| EP-4665730-A1 | HETEROCYCLIC GLP-1 AGONISTS | Gasherbrum Bio, Inc. (US) | 2025-12-24 | — | — | EP | disclosed |
| US-20250304572-A1 | HETEROCYCLIC GLP-1R AGONISTS | BIOMEA FUSION, INC. | 2025-10-02 | — | — | US | disclosed |
| WO-2025119206-A1 | GLP-1 RECEPTOR TARGETING COMPOUNDS AND USES THEREOF | FORTVITA BIOLOGICS INC. (KY) | 2025-06-12 | — | — | WO | disclosed |
| CN-119874775-A | Heterocyclic GLP-1 agonists | 加舒布鲁姆生物公司 | 2025-04-25 | — | — | CN | disclosed |
| CN-119841865-A | Heterocyclic GLP-1 agonists | 加舒布鲁姆生物公司 | 2025-04-18 | — | — | CN | disclosed |
| CN-119823184-A | Heterocyclic GLP-1 agonists | 加舒布鲁姆生物公司 | 2025-04-15 | — | — | CN | disclosed |
| CN-115698003-B | Heterocyclic GLP-1 agonists | 加舒布鲁姆生物公司 | 2024-10-11 | — | — | CN | disclosed |
| WO-2024169952-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. (US) | 2024-08-22 | — | — | WO | disclosed |
| WO-2023016546-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. (US) | 2023-02-16 | — | — | WO | disclosed |
| CN-115698003-A | Heterocyclic GLP-1 agonists | 加舒布鲁姆生物公司 | 2023-02-03 | — | — | CN | disclosed |
| EP-4097099-A1 | HETEROCYCLIC GLP-1 AGONISTS | Gasherbrum Bio, Inc. (US) | 2022-12-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250304572-A1 | HETEROCYCLIC GLP-1R AGONISTS | GLP1R, GPR119, GIPR | RAB9A 676/4885KDM4E 3920/4885ALDH1A1 1711/4885 |
| US-12617783-B2 | Heterocyclic GLP-1R agonists | GLP1R, GIPR, GPR119 | RAB9A 357/4885KDM4E 2335/4885ALDH1A1 2149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.